aTyr Pharma potentially poised to break out in 2025, says RBC Capital

RBC Capital notes that aTyr Pharma announced this morning that patient enrollment is now complete for the Phase 3 EFZO-FIT study in pulmonary sarcoidosis, or PS, calling this “roughly in line with our timeline expectations.” With an important pivotal trial milestone reached, the firm believes “the under-the-radar ATYR is potentially poised to break out in 2025 as a late-stage I&I player to watch,” says the analyst, who has an Outperform rating and $16 price target on aTyr shares.